Radioligand Therapy (RLT) Market Poised to Reach USD 10.91 Billion by 2035, Driven by Advances in Precision Oncology
Radioligand therapy (RLT) is emerging as one of the most promising approaches in precision oncology, offering targeted treatment options for patients with difficult-to-treat cancers. According to recent market research, the global Radioligand Therapy (RLT) Market is projected to grow from USD 3.15 billion in 2025 to USD 10.91 billion by 2035 , registering a robust CAGR of 13.2% during the forecast period. The rapid expansion of the market reflects the growing importance of targeted radiopharmaceuticals in modern cancer care. Increasing cancer incidence, continuous innovation in radiolabeled therapeutics, expanding regulatory approvals, and strategic collaborations among pharmaceutical and biotechnology companies are collectively accelerating market growth. Download PDF Brochure Rising Demand for Precision Oncology Fuels Market Expansion Radioligand therapy combines the specificity of molecular targeting with the cancer-killing effects of radiation. By delivering radioactive ...